Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-770 long-term extension in cystic fibrosis
ACTRN12610000491066Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Long-term safety of VX-770. Started Jul 2010; status: active, not recruiting.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on ACTRN12610000491066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000491066.